Shkreli’s lifetime ban upheld
Martin Shkreli cannot return to the pharmaceuticals industry because his illegal monopolisation of a HIV medicine threatened lives and is likely to reoccur, a federal appellate court has ruled.
Subscribe to Global Competition Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10